REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Annual Statement of Cash Flows
2024-01-01 to 2024-12-31
Statement of Cash Flows
2024-01-01 to 2024-12-31
Swipe to see the full flow
Chart details
REGENERON PHARMACEUTICALS, INC. cash flow reconciliation, Jan 1, 2024 through Dec 31, 2024
Cash flows for Jan 1, 2024 through Dec 31, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Dec 31, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.
- Beginning cash on Dec 31, 2023
- 2,737,800,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- Operating activities
- 4,420,500,000 US dollars. Net cash provided.
- Net income
- 4,412,600,000 US dollars
- Depreciation and amortization
- 482,900,000 US dollars
- Stock-based compensation expense
- 982,800,000 US dollars
- (Gains) losses on marketable and other securities, net
- negative 118,300,000 US dollars
- Other non-cash items, net
- 23,500,000 US dollars
- Deferred income taxes
- negative 757,300,000 US dollars
- (Increase) decrease in accounts receivable
- negative 554,000,000 US dollars
- Increase in inventories
- negative 619,700,000 US dollars
- Increase in prepaid expenses and other assets
- negative 407,500,000 US dollars
- Increase in deferred revenue
- 227,800,000 US dollars
- Increase (decrease) in accounts payable, accrued expenses, and other liabilities
- 735,100,000 US dollars
- Acquired in-process research and development in connection with asset acquisition
- 12,600,000 US dollars
- Investing activities
- negative 2,468,100,000 US dollars. Net cash used.
- Payments for Libtayo intangible asset
- negative 125,700,000 US dollars
- Purchases of marketable and other securities
- negative 16,617,400,000 US dollars
- Capital expenditures
- negative 755,900,000 US dollars
- Acquisitions, net of cash acquired
- negative 16,500,000 US dollars
- Sales or maturities of marketable and other securities
- 15,027,300,000 US dollars
- Proceeds from sale of property, plant, and equipment
- 20,100,000 US dollars
- Financing activities
- negative 2,200,500,000 US dollars. Net cash used.
- Proceeds from issuance of Common Stock
- 1,465,300,000 US dollars
- Other
- negative 33,400,000 US dollars
- Payments in connection with Common Stock tendered for employee tax obligations
- negative 1,029,100,000 US dollars
- Repurchases of Common Stock
- negative 2,603,300,000 US dollars
- Operating adjustment reconciliation
- 2,464,700,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- financing gross reconciliation
- 3,665,800,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- investing gross reconciliation
- 17,515,500,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- Exchange-rate effect
- negative 700,000 US dollars
- Ending cash on Dec 31, 2024
- 2,489,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- Cash sources and uses
- 7,158,300,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- Net cash change
- negative 248,800,000 US dollars. Ending cash minus beginning cash.
- Cash flow / Net income
- 1.00×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
- Operating cash flow
- 4,420,500,000 US dollars. Operating cash flow used in the free cash flow calculation.
- cash spent on productive assets
- 755,900,000 US dollars. These cash purchases are already included in investing activities above.
- Free cash flow
- 3,664,600,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.
Chart connections
- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $7.90M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash spent on productive assets equals free cash flow: 4,420,500,000 US dollars minus 755,900,000 US dollars equals 3,664,600,000 US dollars.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!